Ultragenyx Pharmaceutical (RARE) has an average buy rating among analysts, with a price target range of $73 to $162. (MT Newswires covers equity, commodity...
Ultragenyx Pharmaceutical (RARE) has an average rating of outperform and price targets ranging from $71 to $186, according to analysts polled by Capital...
Ultragenyx Pharmaceutical (RARE) and Abeona Therapeutics (ABEO) said Tuesday they have entered into an exclusive license agreement for ABO-102, or UX111, a...
Ultragenyx Pharmaceutical (RARE) has an average rating of outperform and price targets ranging from $71 to $186, according to analysts polled by Capital...
| Address | 60 Leveroni Court Novato, California 94949 |
| Phone | +1.415.483.8800 |
| Number of Employees | 610 |
| Recent SEC Filing | 06/29/2022 4 |
| President, Chief Executive Officer & Director | Emil D. Kakkis |
| Chief Financial Officer & Executive Vice President | Mardi C. Dier |
| Chief Technical Operations Officer & Senior VP | Dennis Karl Huang |
| Chief Scientific Office | Samuel C. Wadsworth |
| Price Open | $59.41 |
| Previous Close | $60.24 |
| 52 Week Range | $45.20 - 104.38 |
| Market Capitalization | $4.2 B |
| Shares Outstanding | 69.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/01/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$6.55 |
| Beta vs. S&P 500 | N/A |
| Revenue | $51.5 M |
| Net Profit Margin | -141.65% |
| Return on Equity | -51.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
